Astellas temporarily halts S Korean Gaster-D exports after supplier oversight
This article was originally published in Scrip
Astellas has been ordered to halt exports of the 20mg oral-dissolving tablet formulation of the H2-antagonist Gaster-D (famotidine) to South Korea for three months, because some shipments of the product contained active ingredient made by a manufacturer which had not been approved by the local regulator.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.